To this end, we used a gene signature of ADT resistance derived from human prostate tumors prior to treatment with ADT plus the AR inhibitor enzalutamide, in a neoadjuvant setting (Figure 4A) (NCT02430480) (Karzai et al., 2021; Wilkinson et al., 2021; Ku et al., 2021). This evidence concerns the gene AR and prostate neoplasm.